Literature DB >> 18720915

Study of edema reduction patterns during the treatment phase of complex decongestive physiotherapy for extremity lymphedema.

T Yamamoto1, Y Todo, M Kaneuchi, Y Handa, K Watanabe, R Yamamoto.   

Abstract

Shortening the treatment phase of complex decongestive physiotherapy (CDP) is extremely important both for individual patients and medical economics. In 83 patients with stage II unilateral secondary extremity lymphedema (31 upper extremities and 52 lower extremities), the daily changes in the volume of affected extremities during the treatment phase of CDP were prospectively investigated. For the upper extremity lymphedemas, the biggest change was seen between days 1 (100% residual edema rate) and 2 (46.0 +/- 2.7%; mean +/- SD) of therapy with a 54.0% reduction (p < 0.0001). Between days 2 and 3 (38.0 +/- 2.6%) of therapy, there was an 8.0% reduction (p < 0.05). From days 3 to 6 of therapy, slight changes ranging from 0.2 to 3.2%/day were seen. For the lower extremity lymphedemas, the biggest change was seen between days 1 (100%) and 2 (44.5 +/- 2.1%) of therapy with a 55.5% reduction (p < 0.0001). Between days 2 and 3 (33.5 +/- 2.6%) of therapy, there was an 11.0% reduction (p < 0.001). The daily volume changes from days 4 to 6 were slight, ranging from 0.1 to 1.0%/day. During the treatment phase of CDP, the largest volume changes were seen soon after the start of therapy.

Entities:  

Mesh:

Year:  2008        PMID: 18720915

Source DB:  PubMed          Journal:  Lymphology        ISSN: 0024-7766            Impact factor:   1.286


  8 in total

Review 1.  Management of secondary lymphedema related to breast cancer.

Authors:  Oren Cheifetz; Louise Haley
Journal:  Can Fam Physician       Date:  2010-12       Impact factor: 3.275

2.  The results of the intensive phase of complete decongestive therapy and the determination of predictive factors for response to treatment in patients with breast cancer related-lymphedema.

Authors:  Dilek Keskin; Meltem Dalyan; Sibel Ünsal-Delialioğlu; Ülkü Düzlü-Öztürk
Journal:  Cancer Rep (Hoboken)       Date:  2020-01-03

3.  Impact of aggressive decongestion on the maintenance phase in combined physical therapy for lower extremity lymphedema.

Authors:  Kotaro Suehiro; Noriyasu Morikage; Osamu Yamashita; Yohikazu Okazaki; Kimikazu Hamano Md
Journal:  Ann Vasc Dis       Date:  2011-11-15

Review 4.  Manual lymphatic drainage treatment for lymphedema: a systematic review of the literature.

Authors:  Belinda Thompson; Katrina Gaitatzis; Xanne Janse de Jonge; Robbie Blackwell; Louise A Koelmeyer
Journal:  J Cancer Surviv       Date:  2020-08-15       Impact factor: 4.442

5.  A retrospective study of lymphatic transverse rectus abdominis myocutaneous/deep inferior epigastric perforator flaps for breast cancer treatment-induced upper-limb lymphoedema.

Authors:  Zhuangqing Yang; Sheng Huang; Jiankui Wang; Yan Xi; Xiaojuan Yang; Qi Tang; Juan Du; Jianyun Nie; Tianning Zou; Shaoqing Zhou; Xueliang Tang; Dedian Chen
Journal:  Sci Rep       Date:  2017-03-06       Impact factor: 4.379

6.  The addition of self-lymphatic drainage to compression therapy instead of manual lymphatic drainage in the first phase of complex decongestive therapy for treatment of breast cancer-related lymphedema: A randomized-controlled, prospective study.

Authors:  Zeynep Tuba Bahtiyarca; Aslı Can; Emel Ekşioğlu; Aytül Çakcı
Journal:  Turk J Phys Med Rehabil       Date:  2018-12-21

7.  Effect of complete decongestive therapy and home program on health- related quality of life in post mastectomy lymphedema patients.

Authors:  Ganeswara Rao Melam; Syamala Buragadda; Adel A Alhusaini; Nisha Arora
Journal:  BMC Womens Health       Date:  2016-05-04       Impact factor: 2.809

8.  Clinical effectiveness of decongestive treatments on excess arm volume and patient-centered outcomes in women with early breast cancer-related arm lymphedema: a systematic review.

Authors:  Eunice Jeffs; Emma Ream; Cath Taylor; Debra Bick
Journal:  JBI Database System Rev Implement Rep       Date:  2018-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.